It has been reported that ursolic acid has anti-tumor activity and it enhances the therapeutic effect of oxaliplatin in colorectal cancer (CRC). However, the underlying mechanisms remain unknown. In the present study, the mechanisms of the enhancement of therapeutic effects through use of ursolic acid were investigated.
It has been reported that ursolic acid has anti-tumor activity and it enhances the therapeutic effect of oxaliplatin in colorectal cancer (CRC). However, the underlying mechanisms remain unknown. In the present study, the mechanisms of the enhancement of therapeutic effects through use of ursolic acid were investigated.
We treated CRC cell lines HCT8 and SW480 with ursolic acid and oxaliplatin and monitored the effects on cell proliferation, apoptosis, reactive oxygen species (ROS) production and drug resistance gene production. We discovered that treatment with a combination of ursolic acid and oxaliplatin resulted in significant inhibition of cell proliferation, significantly increased apoptosis and ROS production, and significant inhibition of drug resistance gene expression. Our study provided evidence that ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by ROS-mediated inhibition of drug resistance.
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| INTRODUCTION
Colorectal cancer (CRC) is the third most diagnosed cancer in men and the second most frequently observed cancer in women worldwide. 1, 2 It is estimated that the annual number of deaths due to colorectal cancer is more than half a million. CRC accounts for 8% of all cancer deaths, making it the fourth leading cause of death from cancer. 3 In China, it is the fifth most common cancer and also the fifth leading cause of cancer-related deaths. In the year 2012, there were over 150 000 deaths caused by CRC in China and the number is still increasing. 4 Therapeutic advances have been made in the past few decades.
Oxaliplatin is a third generation platinum drug with proven activity against colorectal tumors, having become a standard in the management of this malignancy. 5 It is typically administered together with 5-fluorouracil and folinic acid in a combination known as FOLFOX to treat CRC as palliative or adjuvant chemotherapy. 6 Remarkably, the introduction of oxaliplatin in the year 2000 for the treatment of metastatic colorectal cancer led to an important increase not only in objective response rates, improving the percentage of success of metastasis resection, but also in overall survival (OS). However, a major reason for treatment failure is the existence of tumor intrinsic or acquired resistance to oxaliplatin. 5 For this reason, it is of paramount importance to identify and develop novel drugs that can safely and effectively complement or enhance the therapeutic effects of oxaliplatin. It is also important to elucidate the causes underlying this phenomenon to circumvent it, and to uncover better ways of fighting cancer.
Ursolic acid (3b-hydroxy-urs-12-en-28-oicacid, UA) is a pentacyclic triterpenic acid found in a variety of natural plants, including
Chinese medicinal herbs such as Hedyotic diffusa and Prunell avulgaris. 7 It exhibits a broad range of pharmacological effects, such as anti-inflammatory, antiviral, antioxidant and hepatoprotective effects. [8] [9] [10] Ursolic acid has also shown great promise in treating a number of cancers, such as lung cancer, hepatocellular carcinoma, prostate cancer and breast cancer. [11] [12] [13] [14] It is also reported that ursolic acid inhibits the proliferation of certain CRC cell lines, 15 and ursolic acid enhances the therapeutic effects of oxaliplatin in CRC. 16 However, the precise underlying mechanisms remain unknown.
Here we reported that ursolic acid enhanced oxaliplatin-induced inhibition of CRC cell proliferation and induction of apoptosis in CRC cell lines HCT-8 and SW480. The inhibition effect on CRC was also detected in xenograft nude mouse models. The enhanced suppression is correlated to significantly increased reactive oxygen species (ROS) production and decreased expression of drug resistance genes in CRC cells. Thus, our data suggested that ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by ROS-mediated inhibition of drug resistance.
2 | ME TH ODS AND MATERIALS (50% inhibitory concentration) value, which represents the concentration of the drug that demonstrates 50% of cell growth inhibition, was calculated by nonlinear regression analysis using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
| Apoptosis assay
Cells were harvested by trypsinization and then washed twice in icecold PBS. Subsequently, cells were resuspended at a density of 1 9 10 6 cells/mL in 19 binding buffer (Sigma) followed by the addition of 5 lL of annexin V-fluorescein isothiocyanate and 5 lL of propidium iodide (Sigma). Then cells were incubated in the dark at room temperature for 15 minute. Cell death was determined using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and data were analyzed using FlowJo (Flowjo Studio, Carrboro, NC, USA).
| Assessment of reactive oxygen species production
The oxidative conversion of cell-permeable oxidation of 2 0 ,7 0 -dichlorodihydrofluorescein diacetate to fluorescent 2 0 ,7 0 -dichlorodihydrofluorescein was used to assess the generation of intracellular ROS.
After treatment with ursolic acid or oxaliplatin alone or combination, 
| Western blot
A total of 20 lg of protein was loaded onto a 12% SDS-PAGE gel.
After transfer, membranes were blocked by 5% non-fat milk and incu- 
| Quantitative real-time PCR (RT-PCR)
RNA isolation was performed using the RNeasy Mini Kit (Qiagen, GAPDH forward: 5 0 -AACGGGAAGCTTGTCATCAATGGAAA-3 0 reverse:
2.8 | Xenograft nude mouse model 
| Statistical analysis
Data were presented as mean AE SD and obtained from at least 3 independent experiments. Statistical analysis was performed by 1 or 2-way ANOVA, with P-values < .05 considered as statistically significant.
3 | RESULTS
| Ursolic acid enhanced oxaliplatin-mediated suppression of colorectal cancer cells growth in vitro
To identify the cytotoxicity of ursolic acid and oxaliplatin, we first examined the inhibition effect of ursolic acid and oxaliplatin on 48 hour, the cell proliferation was measured. As shown in Figure 1 , ursolic acid or oxaliplatin alone significantly inhibited both HCT8 and SW480 proliferation. The inhibition effects are summarized in Table 3 . The combination of ursolic acid and oxaliplatin showed more cytotoxicity to both cell lines when compared to either treatment alone. Thus, our data indicated that ursolic acid enhanced oxaliplatin-mediated inhibition of CRC cell proliferation.
| Ursolic acid enhanced oxaliplatin induced apoptosis of colorectal cancer cells in vitro
Both ursolic acid and oxaliplatin had been reported to induce apoptosis in cells. 11, [17] [18] [19] We continued to evaluate the apoptosis of HCT8 and SW480 after treatment with ursolic acid and oxaliplatin separately or together. As shown in Figure 2A , both ursolic acid and oxaliplatin significantly induced apoptosis in HCT8 and SW480 cells.
The combination of ursolic acid and oxaliplatin induced significantly more apoptosis when compared to single treatment. Consistent with the apoptosis result, we also identified a significantly increased protein level of cleaved/activated caspase 3, an apoptosis marker/ effector, in treated cells ( Figure 2B ). The combination treatment also resulted in increased protein level of cleaved/activated caspase 3 when compared to single treatment. Thus, our data suggested that ursolic acid enhanced oxaliplatin-induced apoptosis of CRC cells.
| Ursolic acid enhanced oxaliplatin-induced reactive oxygen species production in colorectal cancer cells
Reactive oxygen species played a role as an important inhibitor of cancer cell proliferation and in induction of apoptosis. 20 As treatment of ursolic acid and oxaliplatin promoted apoptosis and inhibited CRC cell proliferation, we examined the ROS production in treated cells. As shown in Figure 3A , treatment with ursolic acid and oxaliplatin separately or in combination significantly increased ROS production in both HCT8 and SW480 cells. Corresponding to the increased ROS level after treatment, the cells also produced significantly increased NADPH, the resource for ROS production (Figure 3B ). This result reflected an increased level of ROS after ursolic acid and oxaliplatin treatment. It has been reported that ROS can activate JNK signaling pathway and promote apoptosis. We also detected the activation JNK signaling pathway in ursolic acid-treated cells (Fig. S1 ), suggesting the role of JNK signaling pathway in ursolic acid-mediated CRC cell apoptosis. Our data suggested that the enhancement of chemosensitivity by ursolic acid is correlated to the increased ROS level. Relative expression values are presented as means AE SD from 3 independent experiments (**P < .01). The data also demonstrated a significant apoptotic increase by combination of ursolic acid and oxaliplatin
| Ursolic acid and oxaliplatin-induced suppression of drug-resistance genes
Our data demonstrated that ursolic acid and oxaliplatin combination treatment significantly enhanced the inhibitory effect in cancer cells by increasing ROS production. ROS has been shown to correlate to drug resistance. 21 Therefore, we next tested the effect of treatment on drug-resistant genes, including permeability glycoprotein (P-gp), MRP and BCRP. As shown in Figure 4A ,B, we tested both the mRNA level and the protein level of these 3 genes and found that both HCT8
and SW480 cells had significantly decreased mRNA and protein levels in all 3 genes after treatment with ursolic acid or oxaliplatin alone, or in combination. The combination treatment resulted in significantly lower mRNA and protein level of all 3 genes when compared to single treatment. Thus, our data suggested that ursolic acid improved chemosensitivity through suppression of drug resistance.
| Knocking down drug resistance genes resulted in increased apoptosis in colorectal cancer cells
As the ursolic acid and oxaliplatin treatment resulted in inhibition of drug resistance gene expression, we further explored the effect of drug resistance genes using the siRNA knocking down approach. The siRNA treatment significantly decreased the expression of these 3 genes in both HCT-8 and SW480 cells ( Figure 5A ). Corresponding to the decreased endogenous level, we detected significantly increased apoptosis in all 3 siRNA-treated HCT-8 and SW480 cells ( Figure 5B ).
Our data suggested the essential role of drug resistance genes in cancer cell survival.
| Antitumor activity of ursolic acid and oxaliplatin in xenograft mouse model
In view of the above in vitro data, we further tested the effects of this combination strategy in vivo. We established HCT-8 and SW480 xenograft mouse models and mice were randomized to 4 groups with different treatment strategies as described in the Materials and Methods. Noticeably, the mice treated with both ursolic acid and oxaliplatin showed the strongest tumor inhibition, indicated by better survival of animals ( Figure 6A ) and smaller tumors (Figure 6B) . Thus, the anti-tumor effect of ursolic acid and oxaliplatin is not only effective in an in vitro model but also in an in vivo model.
| DISCUSSION
Oxaliplatin is a member of the family of platinum-containing chemotherapeutic agents that also includes cisplatin and carboplatin.
Oxaliplatin is administered intravenously. Pharmacokinetically, it is characterized by a short initial phase of distribution and a long final phase of drug removal, which mainly takes place in the kidneys, 48 hour after drug administration. Once inside the cell, it binds to nucleophilic molecules, mainly DNA but also RNA and proteins. As a DNA interacting agent, it mainly forms intrastrand adducts between 2 adjacent guanine residues or guanine and adenine disrupting DNA replication and transcription.
Unfortunately, intrinsic or acquired resistance to oxaliplatinbased combinations is still the major cause of treatment failure. The drug efflux transporters have a key role in pumping out of tumor The data also demonstrated a significant increase in NADPH level by combination of ursolic acid and oxaliplatin, reflecting an increased level of ROS after treatment cells more than 80% of currently used chemotherapeutic drugs.
Specifically, the ABCC subfamily, which comprises the multidrug resistance-associated proteins (MRP), has been shown to be involved in the development of the resistance phenomena associated with platinum drugs. A role of MRP1 and MRP4 has been pointed out in oxaliplatin resistance, as an increased expression and an alteration in N-linked glycosylation of these transporters were associated with a decrease in drug accumulation and an increased oxaliplatin resistance in an ovarian carcinoma in vitro model. 22 The association between oxaliplatin resistance and the MDR1 (P-gp) expression has also been studied. Ekblad and colleagues described an overexpression of MDR1 as a consequence of oxaliplatin resistance acquisition in vitro. 23 In patients with metastatic colorectal cancer undergoing treatment with folic acid, 5-fluorouracil and oxaliplatin (FOLFOX), low BCRP expression was associated with a better response. 24 Thus, it is of paramount importance to identify or develop novel drugs that can enhance the therapeutic effects of oxaliplatin, potentially by targeting drug resistance.
Ursolic acid, 3b-hydroxy-urs-12-en-28-oic-acid, an ursane-type mice without any significant effect on body weight. 26 Shan et al. 16 report that ursolic acid enhances the therapeutic effects of oxaliplantin against CRC both in vitro and in vivo, although the underlying mechanisms are not well elucidated.
In the current study, we first confirmed the anticancer effect of ursolic acid and showed that ursolic acid inhibited proliferation and induced apoptosis in CRC cell lines HCT8 and SW480, and enhanced the cytotoxicity of oxaliplatin. The enhanced inhibition effect was also observed in a mice model. Then, we further elucidated the underlying mechanisms of the inhibitory effect of ursolic acid. We found that the inhibition effect was associated with increased production of ROS. Usually, an increase in ROS is associated with abnormal cancer cell growth and reflects a disruption of redox homeostasis due either to an elevation of ROS production or to a decline of ROS-scavenging capacity, a condition known as oxidative stress. 27 Because the increase of ROS in cancer cells may play an important part in the initiation and progression of cancer, such intrinsic oxidative stress is often viewed as an adverse event. However, as excessive levels of ROS stress can also be toxic to the cells, The relationship between ROS and cancer drug resistance has been reported. 21, 29 It has been shown that ROS could also work as a negative regulator to downregulate drug resistance gene P-gp expression. 30, 31 In this study, we demonstrated that the treatment of ursolic acid and oxaliplatin in combination significantly suppressed both mRNA and protein levels of drug resistance genes P-gp, MRP and BCRP, possibly through enhanced production of ROS. Knocking down the endogenous protein level of these 3 proteins by siRNA transfection also resulted in enhanced apoptosis in CRC cell lines, indicating a significant role of drug resistance genes in CRC development.
Thus, our data suggested that targeting drug resistance gene expression could be a potential approach to enhance the therapeutic effects of oxaliplatin.
Our study showed that ursolic acid enhanced the therapeutic effects of oxaliplatin. Ursolic acid and oxaliplatin treatment resulted in increased inhibition of proliferation and increased apoptosis in CRC cells. These pheromones were correlated with significantly increased ROS production and decreased expression of drug resistance genes P-gp, MRP and BCRP. Thus, our study demonstrated that ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by ROS-mediated inhibition of drug resistance, F I G U R E 5 Knocking down the drug resistance genes promotes apoptosis. A, Knocking down efficiency of P-gp, MRP and BCRP after siRNA transfection in HCT8 and SW480 cells was detected by real-time PCR and western blotting.
Relative expression values are presented as means AE SD from 3 independent experiments (**P < .01). B, Annexin-V/ propidium iodide double-staining assay was performed to detect the apoptosis levels of HCT8 and SW480 cells after the drug resistance genes were knocked down.
Relative expression values are presented as means AE SD from 3 independent experiments (**P < .01) suggesting a possible therapeutic effect of ursolic acid in treating cancer. However, currently, ursolic acid itself is used in certain local district. To enable worldwide usage of ursolic acid, more studies need to be followed up to analyze its stability and activity, and biological effect mechanisms.
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